The Career Development Program supports young Investigators pursuing careers in translational lymphoma research and also supports established investigators who wish to refocus their work on lymphoma. This program supports two individuals per year and provides 1-2 years of support for each awardee. The program is co-ordinated by the Administrative Core with oversight from the Executive Committee and Advisory Board. The program has well-defined processes for candidate recruitment, and will continue its successful efforts to recruit women and minorities. Both MD and PhD trainees selected by this program will be able to take advantage of courses available through the Clinical Scientist Training Program at BCM and will have a strong group of mentors with broad translational expertiseOijr mentoring strategies enhance the training program by providing trainees with multiple mentors who possess complementary skills, and planning Individualized training schemes. Additionally, trainees have access to the SPORE cores (clinical research, biostatistics, cell processing and vector production) which provide them with unique expertise in cell and gene therapy and clinical research. In the last 4 years, 6 trainees have been supported by this program and all have subsequently obtained independent peer-reviewed funding;three are now Incorporated Into SPORE projects.
The goal of this program is to provide training in translational research In lymphoma, thereby Increasing the number of well qualified and trained investigators jn basic science, population science and clinical research who will contribute to improving lymphoma treatment.
|Iwahori, Kota; Kakarla, Sunitha; Velasquez, Mireya P et al. (2015) Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 23:171-8|
|Ngo, Minhtran Charlotte; Ando, Jun; Leen, Ann M et al. (2014) Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother 37:193-203|
|Ok, Chi Young; Li, Ling; Xu-Monette, Zijun Y et al. (2014) Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 20:2338-49|
|Bollard, Catherine M; Gottschalk, Stephen; Torrano, Vicky et al. (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32:798-808|
|Rouce, Rayne H; Louis, Chrystal U; Heslop, Helen E (2014) Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol 21:476-81|
|Leen, Ann M; Heslop, Helen E; Brenner, Malcolm K (2014) Antiviral T-cell therapy. Immunol Rev 258:12-29|
|Xu, Xin; Hegazy, Wael A H; Guo, Linjie et al. (2014) Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res 74:6260-70|
|Zhou, Xiaoou; Di Stasi, Antonio; Tey, Siok-Keen et al. (2014) Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123:3895-905|
|Papadopoulou, Anastasia; Krance, Robert A; Allen, Carl E et al. (2014) Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther 22:1134-8|
|Anurathapan, Usanarat; Leen, Ann M; Brenner, Malcolm K et al. (2014) Engineered T cells for cancer treatment. Cytotherapy 16:713-33|
Showing the most recent 10 out of 121 publications